Eli Lilly Expands China Cancer Reach
Eli Lilly NYSE:LLY is expanding its China oncology reach through a new commercialization agreement with Innovent Biologics for Verzenios.Under the deal, Innovent will handle importation, marketing, distribution and promotion of Verzenios in mainland China. The breast cancer drug, also known as abem…
Hybio's generic weight-loss drug set for FDA review
The U.S. Food and Drug Administration has agreed to review Chinese generics drugmaker Hybio Pharmaceutical's SZSE:300199 two experimental generic tirzepatide GLP-1s that, if approved, would rival obesity and diabetes drugs made by Eli Lilly NYSE:LLY.
Eli Lilly transfers commercialization rights for breast cancer drug in China amid generic competition
By Andrew SilverEli Lilly has transferred the mainland China commercialization rights for its breast cancer drug Verzenios to Innovent Biologics, the Chinese drugmaker said Tuesday, as its U.S. partner grapples with generic competition in the world's second-largest pharmaceutical market.In a statem…
China's Innovent Biologics gains commercialization rights for Eli Lilly breast cancer drug
Innovent Biologics HKEX:1801 has entered into an agreement that grants it sole commercialization rights for Eli Lilly's NYSE:LLY breast cancer drug Verzenios in mainland China, the Chinese drugmaker said Tuesday.Lilly will continue manufacturing, supplying and developing the drug, it said in a stat…
Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic…
Medicare Begins Obesity Drug Coverage, Seniors Unaware Of New Benefit
WASHINGTON (dpa-AFX) - Starting Wednesday, millions of older Americans on Medicare can now get obesity medications through a new initiative called the Bridge program. This program allows qualifying folks to pay a monthly copay of $50 for access to popular weight-loss drugs by Novo Nordisk and Eli L…
Lilly, Regeneron selected for US program to review new manufacturing plants faster
The U.S. Food and Drug Administration on Monday selected Eli Lilly NYSE:LLY, Regeneron NASDAQ:REGN and five other companies for a pilot program to accelerate reviews of new domestic pharmaceutical manufacturing facilities.Drugmakers, including Lilly and Regeneron, are pledging billions to shift mor…
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
The U.S. Food and Drug Administration has selected Eli Lilly NYSE:LLY and Regeneron NASDAQ:REGN, among seven companies, for a pilot program to accelerate reviews of new domestic pharmaceutical manufacturing facilities, CNBC reported on Monday citing an FDA spokesperson.
Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
ELI LILLY, REGENERON AMONG FIRST COMPANIES SELECTED FOR FDA INITIATIVE TO SPEED REVIEW OF NEW MANUFACTURING FACILITIES - CNBC
Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs
On Friday, stocks of four large drugmakers, Eli Lilly LLY, AbbVie ABBV, J&J JNJ and Biogen BIIB hit fresh 52-week highs. However, the rally in the four stocks was not driven by a single catalyst, but by an overall recent rally in the U.S. drug and biotech sector.The S&P Healthcare Index (XLV) has g…
Here's Why Shares of Eli Lilly Hit an All-Time High on Friday
Shares of Eli Lilly LLY rose more than 7% on Friday after the company announced several positive developments related to its marketed products.An EMA advisory committee recommended approving the company’s filing seeking label expansion for the oncology drug Jaypirca (pirtobrutinib) to treat adults…
FDA set to review Sandoz's generic GLP-1s
The U.S. Food and Drug Administration has agreed to review Swiss generics drugmaker Sandoz's SIX:SDZ two generic tirzepatide GLP-1s that, if approved, would rival obesity drugs made by Eli Lilly NYSE:LLY.With Eli Lilly's tirzepatide patent running out in 2036 in the U.S., makers of alternative drug…
Key facts: Medicare GLP‑1 Bridge starts Jul 1; CHMP backs Jaypirca
Medicare’s GLP‑1 Bridge starts July 1, 2026, giving eligible beneficiaries access to Eli Lilly weight‑loss drugs Zepbound and Foundayo for a $50 monthly copay.EU CHMP recommended E